Market research
ZIVO Zivo Bioscience Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 12
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98978N2009
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 12
- Beta
- Not available
About
About Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZIVO discussion.
5 years, 4 months ago
Zivo Bioscience, Inc. Common Stock is currently in a long term uptrend where the price is trading 492.1% above its 200 day moving average.
From a valuation standpoint, the stock is 97.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2639.2.
Zivo Bioscience, Inc. Common Stock's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 12.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 34.3% to $-1M since the same quarter in the previous year.
Based on the above factors, Zivo Bioscience, Inc. Common Stock gets an overall score of 2/5.